Global Chronic Obstructive Pulmonary Disease Treatment Market: Overview This report analyzes the current and future scenario of the global chronic obstructive pulmonary disease (COPD) treatment market.Rise in prevalence of COPD, increase in the adoption of combination therapy, and surge in awareness about COPD treatment are the key factors anticipated to drive the global market.
Additionally, increase in the geriatric population, rise in importance of COPD management, and surge in the number of respiratory care centers contribute to the growth of the global market. According to the Global Initiative for Asthma (GINA) 2018, COPD is the third leading cause of death in the U.S., with large portion of population being undiagnosed.
The global chronic obstructive pulmonary disease treatment market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market.It also provides information and data analysis of the global market with respect to the segments based on drug class, distribution channel, and region.
A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section.Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market.
This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global chronic obstructive pulmonary disease treatment market.
New drug development by market players through collaborations and increase in research and development expenditure are anticipated to drive the global market.In February 2016, Propeller Health and Novartis Pharma AG entered into collaboration to develop a custom add-on sensor for the Breezhaler inhaler, a device indicated for COPD treatments.
This collaboration aims to connect these medications to Propeller’s digital health platform..
Global Chronic Obstructive Pulmonary Disease Treatment Market: Key Segments In terms of drug class, the global chronic obstructive pulmonary disease treatment market has been segmented into combination, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitors, mucokineticsm and others.The combination segment has been divided into long acting muscarinic antagonist & inhaled corticosteroids (LAMA-ICS), long acting beta agonist & inhaled corticosteroids (LABA-ICS), triple therapy, and others.
The bronchodilators segment has been classified into long acting beta agonist (LABA), short acting beta agonist (SABA), and long acting muscarinic antagonist (LAMA).Based on distribution channel, the market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies.
The retail pharmacies segment is projected to expand at the fastest CAGR due to increase in the number of patients preferring retail pharmacies. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.
Global Chronic Obstructive Pulmonary Disease Treatment Market: Regional Outlook In terms of region, the global chronic obstructive pulmonary disease treatment market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.
Companies Mentioned in Report The report also profiles major players in the global chronic obstructive pulmonary disease treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Key players profiled in the market report include AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline plc, Novartis AG, CHIESI Farmaceutici S.p.A., Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd), Teva Pharmaceutical Industries Ltd, Mylan N.V., and Orion Corporation.
The global chronic obstructive pulmonary disease treatment market has been segmented as below: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Drug Class Combination Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS) Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS) Triple Therapy Others
Bronchodilators Long Acting Beta Agonist (LABA) Short Acting Beta Agonist (SABA) Long Acting Muscarinic Antagonist (LAMA) Corticosteroids Phosphodiesterase Type 4 Inhibitors Mucokinetics Others
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies
Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Region North America U.S. Canada Europe Germany U.K. Italy France Spain Rest of Europe Asia Pacific India China Japan Australia & New Zealand Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa GCC Countries South Africa Israel Rest of Middle East & Africa
Our reports have been used by over 10K customers, including:
Peritonitis Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Peritonitis Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Peritonitis Clinical trials scenario.This report provides top line data relating to the clinical trials on Peritonitis. Report...
Bronchiectasis - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Bronchiectasis - Pipeline Review, H2 2020, provides an overview of the Bronchiectasis (Respiratory) pipeline landscape. Bronchiectasis is a chronic condition where the walls of...
Type 2 Angiotensin II Receptor - Pipeline Review, H2 2020 Summary Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene. AT2 receptor is highly expressed in the developing foetus, but its expression...